Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Characterization of 6-Mercaptopurine Transport by the SLC43A3-Encoded Nucleobase Transporter

Nicholas M. Ruel, Khanh H. Nguyen, Gonzalo Vilas and James R. Hammond
Molecular Pharmacology June 2019, 95 (6) 584-596; DOI: https://doi.org/10.1124/mol.118.114389
Nicholas M. Ruel
Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khanh H. Nguyen
Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gonzalo Vilas
Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James R. Hammond
Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Predicted topology of ENBT1. Sequence shown is for the protein encoded by SLC43A3_1 (ENBT1.1). The 13 amino acid insert in ENBT1.2 (encoded by SLC43A3_2) after the alanine at position 61 is indicated. Structure was generated with Protter (http://wlab.ethz.ch/protter/start/) (Omasits et al., 2014).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Stable transfection of HEK293 cells with SLC43A3_1 and SLC43A3_2. (A) Transfection of HEK293 cells with SLC43A3 was confirmed using PCR with the primers specific for SLC43A3 (top) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (bottom) shown in (Supplemental Table 1). cDNA was prepared from total RNA isolated from untransfected cells (HEK293) or HEK293 cells stably transfected with SLC43A3_1 or SLC43A3_2. (B) Membranes were prepared from HEK293 cells and cells transfected with SLC43A3_1 (ENBT1.1) and SLC43A3_2 (ENBT1.2). Samples were resolved on SDS-PAGE gels, transferred to polyvinyl membranes and probed with anti-SLC43A3 and anti-β-actin antibodies. (C) Parallel immunoblot analyses were performed as described previously, but using anti-myc and anti-β-actin antibodies.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Compensatory changes in gene expression upon transfection of HEK293 cells with SLC43A3. Gene expression, assessed by semiquantitative PCR, is shown relative to the amount detected in untransfected HEK293 cells. Expression was normalized to glyceraldehyde-3-phosphate dehydrogenase transcript levels in each individual experiment. (A) Relative expression of SLC43A3 in HEK293 cells stably transfected with the respective SLC43A3_1, SLC43A3_2, or empty vector (pcDNA3.1) construct (N = 5). (B–D) Relative expression of ENT1 (SLC29A1), ENT2 (SLC29A2), ENT4 (SLC29A4), MRP4 (ABCC4), and MRP5 (ABCC5), and the enzymes TPMT and hypoxanthine-guanine phosphoribosyltransferase (HPRT) in HEK293 cells transfected with either empty pcDNA3.1 (B), SLC43A3_1 (C), or SLC43A3_2 (D). Bars represent the mean ± S.D. of five independent samples; * denotes significant difference in expression between untransfected HEK293 cells and transfected HEK293 cells (Student’s t test, P < 0.05, corrected for multiple comparisons with the Holm-Sidak method).

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    [3H]Adenine transport by SLC43A3-encoded ENBT1. HEK293 cells and cells transfected with SLC43A3_1 (A), SLC43A3_2 (B), or the empty pcDNA3.1 vector (B) were incubated with 100 µM [3H]adenine at room temperature for the specified times (abscissa) and then centrifuged through oil. Cell pellets were digested overnight in 1 M NaOH and assessed for [3H] content using standard liquid scintillation counting techniques to define picomoles of adenine accumulated per microliter cell pellet (ordinate). ENBT1-mediated uptake was defined as the difference in cellular accumulation by the SLC43A3-transfected cells (SLC43A3-HEK293) and that observed in the untransfected HEK293 cells assessed in parallel. Data points represent the mean ± S.D. of six (A) or five (B) experiments done in duplicate. (C) The kinetics of ENBT1.1- and ENBT1.2-mediated uptake of [3H]adenine were determined by assessing the uptake of a range of concentrations of [3H]adenine (abscissa) as described for (A and B). Initial rates of influx (ordinate) were estimated as the transporter-mediated uptake at 0.5 seconds extrapolated from time course profiles as shown in (A) (ENBT1.1) or directly from the 2-second uptake time point (B) (ENBT1.2). Data shown are the mean ± S.D. of N = five experiments.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    [14C]6-MP transport by SLC43A3-encoded ENBT1. HEK293 cells and cells transfected with SLC43A3_1 (A), SLC43A3_2 (B), or empty pcDNA3.1 (B) were incubated with 100 µM (A) or 30 µM (B) [14C]6-MP at room temperature, in the presence and absence of 1 mM adenine, for the specified times (abscissa) and then centrifuged through oil. Cell pellets were digested overnight in 1 M NaOH and assessed for [14C] content using standard liquid scintillation counting techniques to define pmol 6-MP accumulated per microliter cell pellet (ordinate). Data points represent the mean ± S.D. of seven (A) or five (B) experiments done in duplicate. (C) The kinetics of ENBT1.1- and ENBT1.2-mediated [14C]6-MP uptake were determined by assessing the uptake of a range of concentrations of [14C]6-MP (abscissa) as described for (A and B). Initial rates of influx (ordinate) were estimated as the transporter-mediated uptake (calculated as the difference in cellular uptake ± adenine) at 0.5 seconds interpolated from time course profiles as shown in (A) (ENBT1.1), or directly from the 2-second uptake time point (ENBT1.2). Data shown are the mean ± S.D. of N = 5 experiments.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Inhibition of [14C]6-MP transport by SLC43A3-transfected HEK293 cells. The uptake of [14C]6-MP by ENBT1.1 (100 µM) (A) and ENBT1.2 (30 µM) (B) was assessed using a 2-second time point in the presence and absence of the indicated concentration of MTX, 6-TG, MMP, 2-chloroadenosine (Cl-Ado), adenosine (Ado), 2-deoxyadenosine (Deoxy-Ado), hypoxanthine (Hypox), uridine, nitrobenzylthioinosine (NBMPR), or decynium-22 (D22). Data were normalized as percentage of control uptake, where 100% was defined as the uptake of [14C]6-MP in the absence of inhibitor and 0% was defined as the uptake in the presence of 1 mM adenine. Each bar represents the mean ± S.D. of five experiments done in duplicate; * denotes significantly different from 100% control (Student’s t test, P < 0.05, corrected for multiple comparisons with the Holm-Sidak method). (C) Time courses were constructed at various concentrations of [3H]adenine in the presence of 750 µM 6-TG, as described previously (see Fig. 4C). Initial rates of transport were derived from the rate of uptake at 0.5 seconds as extrapolated from the time course profiles. The dashed line indicates the analogous data obtained in the absence of 6-TG (from Fig. 4C). Data points represent mean ± S.D. of five experiments done in duplicate. (D) A range of concentrations of 6-TG, MMP, and D22 were assessed for their ability to inhibit the 2-second uptake of 100 µM [14C]6-MP by the ENBT1.1. Data were normalized as the percentage of control uptake with 100% defined as the uptake of 100 µM [14C]6-MP in the absence of inhibitor and 0% defined as that in the presence of 1 mM adenine. Sigmoid curves were fitted to these data for the determination of IC50 values, which were used to calculate the inhibitor Ki values shown in the text. Each point represents the mean ± S.D. of N = 5 experiments done in duplicate.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    6-MP efflux by ENBT1.1. Cells were loaded with 100 µM [14C]6-MP for 30 seconds (SLC43A3_1 transfected) or 10 minutes (untransfected HEK293), pelleted, and then to initiate efflux suspended in either N-methylglucamine buffer (control) or buffer containing either 1 mM or 100 µM adenine. Aliquots of cell suspension were centrifuged through an oil layer at the specified times (abscissa) and processed to assess intracellular [14C] content. Data are expressed as percentage of initial [14C]6-MP load (ordinate) with 100% defined as [14C]6-MP content at zero time extrapolated from the curve fit (one phase exponential decay) to the 1 mM adenine data. One- or two-phase decay profiles were fitted to the data depending on which fit was determined to be statistically superior (P < 0.05; F test). Each point represents the mean ± S.D. of five (control and 100 µM adenine) or 10 (1 mM adenine) experiments.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Effect of ceefourin-1, zaprinast, and DY on 6-MP efflux. SLC43A3_1-transfected HEK293 cells were loaded with 100 µM [14C]6-MP for 30 seconds, pelleted, and then to initiate efflux suspended in either N-methylglucamine buffer (control) or buffer containing either 1 mM or 100 µM adenine, as indicated, in the presence and absence of the MRP4 inhibitor ceefourin-1 (50 µM) (A), the MRP5 inhibitor zaprinast (100 µM) (B), a combination of 50 µM ceefourin-1 and 100 µM zaprinast (C), or the ENT2 inhibitor DY (1 µM) (D). Aliquots of cell suspension were centrifuged through an oil layer at the specified times (abscissa) and processed to assess intracellular [14C] content. Data are expressed as percentage of initial [14C]6-MP load (ordinate), and either a one- or two-phase decay profile was fitted to the data based on which fit was determined to be statistically superior (P < 0.05; F test). Each point represents the mean ± S.D. of five experiments.

  • Fig. 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 9.

    SLC43A3 transfection of HEK293 cells significantly enhances the cytotoxicity of 6-MP. HEK293 cells and cells transfected with empty pcDNA3.1 plasmid or SLC43A3_1 (A) or SLC43A3_2 (B) were plated at a density of 5 × 104 cells/well in 24-well plates and incubated with a range of concentrations of 6-MP (abscissa) for 48 hours at 37°C in a humidified incubator (5% CO2/95% air). Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and expressed as a percentage of the cell viability measured at 48 hours in the absence of 6-MP (percentage of control; ordinate). Biphasic dose-response curves were fitted to these data, and each point represents the mean ± S.D. of five experiments; * denotes significant difference between HEK293 cells and SLC43A3-transfected cells (Student’s t test, P < 0.05, corrected for multiple comparisons with the Holm-Sidak method). (C) Effect of DY on the cytotoxicity of 6-MP. HEK293 cells and cells transfected with SLC43A3_1 were incubated with a range of concentrations of 6-MP in the absence and presence of the ENT1/ENT2 blocker DY (1 µM). Cell viability was assessed and data are presented as described for (A and B) (N = 5). (D) Effect of G418 on the cytotoxicity of 6-MP in SLC43A3_1- and SLC43A3_2-transfected HEK293 cells. Cell viability was assessed upon incubation with the indicated concentrations of 6-MP for 48 hours, as described for (A and B), in the presence (+) and absence (−) of 120 µg/ml G418 (N = 5).

  • Fig. 10.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 10.

    Effect of MRP4 and MRP5 inhibition on the cytotoxicity of 6-MP. HEK293 cells (A) and cells transfected with SLC43A3_1 (B) were exposed to a range of concentrations of 6-MP for 48 hours in the absence (control) and presence of ceefourin-1 (50 µM), zaprinast (100 µM), or a combination of both, and then assessed for cell viability as described in Fig. 9; * denotes significant difference between control and ceefourin-1 + zaprinast and # denotes significant difference between control and ceefourin-1 alone (Student’s t test, P < 0.05, corrected for multiple comparisons with the Holm-Sidak method, N = 6). (C) HEK293 cells and cells transfected with SLC43A3_1 were stably transfected with ABCC4 (MRP4)-targeted siRNA. The cytotoxicity of a range of concentrations of 6-MP was then assessed in these cells lines as described in Fig. 9; * denotes significant effect of siRNA in SLC43A3_1-transfected HEK293 cells and # denotes significant effect of siRNA in untransfected HEK293 cells (Student’s t test, P < 0.05, corrected for multiple comparisons with the Holm-Sidak method, N = 5). (D) ABCC4 transcript levels (±siRNA transfection) in the untransfected and SLC43A3_1-transfected HEK293 cells used for the experiments shown in (C). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript levels were determined in parallel for each cell line to correct for loading differences. Densitometry analysis indicates that the ABCC4 transcript was suppressed by ∼60% in the siRNA-transfected cells.

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Table -

      Supplemental Table 1 - PCR Primer Sequences

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 95 (6)
Molecular Pharmacology
Vol. 95, Issue 6
1 Jun 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of 6-Mercaptopurine Transport by the SLC43A3-Encoded Nucleobase Transporter
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Cellular Uptake of 6-Mercaptopurine

Nicholas M. Ruel, Khanh H. Nguyen, Gonzalo Vilas and James R. Hammond
Molecular Pharmacology June 1, 2019, 95 (6) 584-596; DOI: https://doi.org/10.1124/mol.118.114389

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Cellular Uptake of 6-Mercaptopurine

Nicholas M. Ruel, Khanh H. Nguyen, Gonzalo Vilas and James R. Hammond
Molecular Pharmacology June 1, 2019, 95 (6) 584-596; DOI: https://doi.org/10.1124/mol.118.114389
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics